Wedbush Downgrades Praxis Precision Medicines Inc. (PRAX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PRAX Hot Sheet
Price: $252.96 -2.3%
Rating Summary:
19 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
19 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Wedbush analyst Laura Chico downgraded Praxis Precision Medicines Inc. (NASDAQ: PRAX) from Outperform to Neutral with a price target of $4.00 (from $34.00).
For an analyst ratings summary and ratings history on Praxis Precision Medicines Inc. click here. For more ratings news on Praxis Precision Medicines Inc. click here.
Shares of Praxis Precision Medicines Inc. closed at $8.59 yesterday.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Graco Inc. (GGG) PT Lowered to $80 at DA Davidson
- Third Coast Bancshares Inc (TCBX) PT Lowered to $54 at StoneX
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
